肿瘤细胞治疗研究
FRONTIER PAPERS
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours.
我们确定并全面验证了OR7A10，一种G蛋白偶联受体（GPCR），作为最佳候选。
A new immunotherapy ROR: Proximal ROR1 domain targeting breast cancer via monoclonal antibodies and CAR NK cells.
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.
受体酪氨酸激酶样孤儿受体1 (ROR1) 是肿瘤免疫治疗中一个新兴的靶点，因其在包括三阴性乳腺癌 (TNBC) 在内的多种上皮性肿瘤中持续且高表达而受到认可。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Chimeric antigen receptor NK cells for breast cancer immunotherapy.
乳腺癌是全球女性中最常见的恶性肿瘤，需要超越手术、化疗、放疗和内分泌治疗等传统疗法的创新治疗策略。
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
乳腺癌细胞上ICAM-1的下调是逃逸trastuzumab触发的ADCC的关键机制。相反，CAR-NK细胞能够克服由ICAM-1减少引起的癌细胞耐药，凸显了CAR-NK细胞在肿瘤免疫治疗中的潜力。
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy.
HER2 阳性乳腺癌脑转移（HER2 + BCBM）是一种复发率高、预后差的难治性恶性肿瘤。
Construction of anti-HER2 affibody-directed CAR-NK and its synergistic effects with doxorubicin-loaded nanodrug against HER2-positive breast cancer.
这些发现表明，基于亲和体的 CAR-NK 细胞是传统基于 scFv 的 CAR 结构的可行替代方案。
Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.
体外实验中，在效靶比（E:T）为0.1:1时，ROBO1 CAR-NK92-Cbl-b-KO细胞（50.55%）与ROBO1阳性T47D靶细胞共培养3小时后，其细胞杀伤活性显著高于ROBO1 CAR-NK92（34.10%）、NK92-Cbl-b-KO（22.22%）和亲本NK-92细胞（3.28%）。
MEMBER ACCOUNT
登录成功会直接打开下一页。
